<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068743</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-121</org_study_id>
    <nct_id>NCT01068743</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered</brief_title>
  <official_title>Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 850 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 850 mg Metformin (Glucophage Marketed by Merck Serono) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination
      (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage
      Marketed by Merck-Serono) tablet co-administered to healthy subjects in the fasted and fed
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin PK Parameter AUC(0-inf)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin PK Parameter Cmax</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-hydroxy Saxagliptin PK Parameter AUC(0-inf)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-hydroxy Saxagliptin PK Parameter Cmax</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).</measure>
    <time_frame>AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
    <description>Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Saxagliptin PK Parameter AUC(0-t)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Saxagliptin PK Parameter T1/2</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Saxagliptin PK Parameter Tmax</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metformin PK Parameter AUC(0-t)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metformin PK Parameter T1/2</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metformin PK Parameter Tmax</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>Tablets, Oral, 2.5 mg, once daily, single dose</description>
    <arm_group_label>Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)</arm_group_label>
    <arm_group_label>Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Tablets, Oral, 850 mg, once daily, single dose</description>
    <arm_group_label>Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)</arm_group_label>
    <arm_group_label>Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin + metformin (FDC tablet)</intervention_name>
    <description>Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose</description>
    <arm_group_label>Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)</arm_group_label>
    <arm_group_label>Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18 to 55 inclusive

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, electrocardiograms (ECGs), and clinical
             laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m^2, inclusive. BMI = weight (kg)/ [height (m)]^2

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months) gastrointestinal disease

          -  Any major surgery within 4 weeks of study drug administration

          -  History of allergy to a dipeptidyl peptidase-IV (DPP4) inhibitor or related compound

          -  History of allergy or intolerance to metformin or other similar acting agents

          -  Prior exposure to saxagliptin

          -  Prior exposure to metformin within 3 months of study drug administration

          -  Estimated creatinine clearance (Clcr) of &lt; 80 mL/min using the Cockcroft Gault formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <results_first_submitted>January 9, 2012</results_first_submitted>
  <results_first_submitted_qc>January 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2012</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants (N = 24) who met all of the inclusion and none of the exclusion criteria were recruited from a single site in the United States.</recruitment_details>
      <pre_assignment_details>Participants were screened for eligibility within 21 days before Day 1 of period 1. On Day −1 of each period, the participants were admitted to the clinical facility and confined for 4 days. All the 24 participants were randomly assigned to 1 of 4 treatment sequences (ADBC, BACD, CBDA, or DCAB). The washout between each dose was at least 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ADBC</title>
          <description>Treatment A (period 1): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment D (period 2): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment B (period 3): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment C (period 4): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence BACD</title>
          <description>Treatment B (period 1): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment A (period 2): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment C (period 3): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment D (period 4): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence CBDA</title>
          <description>Treatment C (period 1): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment B (period 2): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition; Treatment D (period 3): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment A (period 4): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence DCAB</title>
          <description>Treatment D (period 1): Fixed dose combination (FDC) tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition; Treatment C (period 2): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fed condition; Treatment A (period 3): 2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition; Treatment B (period 4): FDC tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled and Treated Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.2" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.23" spread="18.52"/>
                    <measurement group_id="O2" value="49.94" spread="19.72"/>
                    <measurement group_id="O3" value="52.50" spread="17.95"/>
                    <measurement group_id="O4" value="53.15" spread="17.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>101.45</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.17</ci_lower_limit>
            <ci_upper_limit>104.84</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries. LS=Least Squares.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf,respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>102.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.53</ci_lower_limit>
            <ci_upper_limit>105.42</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>49.23</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>49.94</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>52.71</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>53.99</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-hydroxy Saxagliptin PK Parameter AUC(0-inf)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>5-hydroxy Saxagliptin PK Parameter AUC(0-inf)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.58" spread="24.08"/>
                    <measurement group_id="O2" value="119.54" spread="21.16"/>
                    <measurement group_id="O3" value="121.99" spread="25.42"/>
                    <measurement group_id="O4" value="125.54" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-hydroxy Saxagliptin PK Parameter Cmax</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>5-hydroxy Saxagliptin PK Parameter Cmax</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.83" spread="32.95"/>
                    <measurement group_id="O2" value="16.72" spread="32.92"/>
                    <measurement group_id="O3" value="17.35" spread="32.95"/>
                    <measurement group_id="O4" value="18.59" spread="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="20.44"/>
                    <measurement group_id="O2" value="9.97" spread="29.07"/>
                    <measurement group_id="O3" value="10.25" spread="26.87"/>
                    <measurement group_id="O4" value="10.88" spread="23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>102.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.68</ci_lower_limit>
            <ci_upper_limit>110.88</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 98% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively. If there was a 5% difference, then 20 participants would have provided 93% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>106.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.43</ci_lower_limit>
            <ci_upper_limit>114.66</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>9.73</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>9.97</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>10.33</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>10.97</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin PK Parameter AUC(0-inf)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter AUC(0-inf)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11998.00" spread="23.68"/>
                    <measurement group_id="O2" value="12271.61" spread="20.42"/>
                    <measurement group_id="O3" value="11988.30" spread="16.94"/>
                    <measurement group_id="O4" value="11838.11" spread="18.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>102.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.26</ci_lower_limit>
            <ci_upper_limit>107.18</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>99.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.23</ci_lower_limit>
            <ci_upper_limit>102.21</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for Treatment A.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>11998</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>12250</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>12036</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>11937</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin PK Parameter Cmax</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter Cmax</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1724.38" spread="25.49"/>
                    <measurement group_id="O2" value="1715.79" spread="23.59"/>
                    <measurement group_id="O3" value="1571.21" spread="15.64"/>
                    <measurement group_id="O4" value="1541.76" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (B/A) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>99.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.41</ci_lower_limit>
            <ci_upper_limit>109.5</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of saxagliptin and metformin tablets under both fasted and fed conditions, then 20 participants would have provided 99% power to conclude BE with respect to each of Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would provide 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf of metformin.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>98.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.28</ci_lower_limit>
            <ci_upper_limit>102.32</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL</param_type>
            <param_value>1724.4</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Square Means (ng/mL)</param_type>
            <param_value>1715.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean (ng/mL)</param_type>
            <param_value>1581.4</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>1553.2</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.60" spread="25.81"/>
                    <measurement group_id="O2" value="110.61" spread="22.77"/>
                    <measurement group_id="O3" value="113.15" spread="26.53"/>
                    <measurement group_id="O4" value="117.04" spread="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="1.32"/>
                    <measurement group_id="O2" value="7.58" spread="1.35"/>
                    <measurement group_id="O3" value="7.48" spread="1.10"/>
                    <measurement group_id="O4" value="7.22" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="0.75"/>
                    <measurement group_id="O2" value="1.86" spread="0.71"/>
                    <measurement group_id="O3" value="2.65" spread="0.83"/>
                    <measurement group_id="O4" value="2.46" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
        <time_frame>AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
          <population>All participants who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants With at Least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Saxagliptin PK Parameter AUC(0-t)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin PK Parameter AUC(0-t)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.15" spread="17.98"/>
                    <measurement group_id="O2" value="47.83" spread="19.77"/>
                    <measurement group_id="O3" value="50.69" spread="17.74"/>
                    <measurement group_id="O4" value="51.37" spread="17.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>101.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.07</ci_lower_limit>
            <ci_upper_limit>104.90</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>102.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.56</ci_lower_limit>
            <ci_upper_limit>105.57</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>47.15</param_value>
            <estimate_desc>Geometric least squares means for Treatment A.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>47.83</param_value>
            <estimate_desc>Geometric least squares means for Treatment B.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>50.89</param_value>
            <estimate_desc>Geometric least squares means for Treatment C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>52.17</param_value>
            <estimate_desc>Geometric least squares means for Treatment D.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Saxagliptin PK Parameter T1/2</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin PK Parameter T1/2</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="1.00"/>
                    <measurement group_id="O2" value="6.21" spread="1.25"/>
                    <measurement group_id="O3" value="5.86" spread="0.92"/>
                    <measurement group_id="O4" value="6.09" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Saxagliptin PK Parameter Tmax</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin PK Parameter Tmax</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.79"/>
                    <measurement group_id="O2" value="0.96" spread="0.61"/>
                    <measurement group_id="O3" value="1.94" spread="0.95"/>
                    <measurement group_id="O4" value="1.48" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin PK Parameter AUC(0-t)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter AUC(0-t)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11826.52" spread="23.86"/>
                    <measurement group_id="O2" value="11875.08" spread="21.47"/>
                    <measurement group_id="O3" value="11796.60" spread="17.03"/>
                    <measurement group_id="O4" value="11681.05" spread="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>100.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.40</ci_lower_limit>
            <ci_upper_limit>105.68</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>99.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.19</ci_lower_limit>
            <ci_upper_limit>102.02</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric least squares means values presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>11827</param_value>
            <estimate_desc>Geometric least squares means for Treatment A.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>11875</param_value>
            <estimate_desc>Geometric least squares means for Treatment B.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>11845</param_value>
            <estimate_desc>Geometric least squares means for Treatment C.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*h/mL)</param_type>
            <param_value>11734</param_value>
            <estimate_desc>Geometric least squares means for Treatment D.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin PK Parameter T1/2</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter T1/2</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.</description>
          <population>All treated participants not discontinuing prior to the end of the study. One participant in period 3 (treatment D) was excluded from the pharmacokinetic analysis due to a predose concentration greater than 5% of Cmax.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.94" spread="4.13"/>
                    <measurement group_id="O2" value="13.15" spread="6.67"/>
                    <measurement group_id="O3" value="10.82" spread="3.18"/>
                    <measurement group_id="O4" value="11.13" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin PK Parameter Tmax</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter Tmax</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="0.78"/>
                    <measurement group_id="O2" value="2.54" spread="0.92"/>
                    <measurement group_id="O3" value="3.74" spread="0.54"/>
                    <measurement group_id="O4" value="3.74" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities</title>
        <description>Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.</description>
        <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
        <population>All participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities</title>
          <description>Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.</description>
          <population>All participants who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital Sign Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Examination Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Lead ECG Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>2.5 mg saxagliptin tablet + metformin 850 mg tablet single dose under fasted condition</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Fixed dose combination (FDC) tablet (saxagliptin 2.5 mg + metformin 850 mg) single dose under fasted condition</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>2.5 mg saxagliptin tablet and metformin 850 mg tablet single dose under fed condition</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>FDC tablet (2.5 mg saxagliptin + metformin 850 mg) single dose under fed condition</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period of &lt;= 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trail's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

